D3S-001 is under clinical development by D3 Bio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how D3S-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
D3S-001 overview
D3S-001 is under development for the treatment of solid tumor, unspecified immunological disorders, non-small cell lung cancer, metastatic pancreatic cancer pancreatic ductal adenocarcinoma and metastatic colorectal cancer. It is administered through oral route. It acts by targeting KRAS G12C mutations.
D3 Bio overview
D3 Bio provides healthcare-related services. It is headquartered in Zhejiang, China.
For a complete picture of D3S-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.